ERBB2 and melanoma: Thereby, at different E/T ratios and with both, MDA-MB-453 breast carcinoma cells that highly overexpress ErbB2 and MZ-Mel-2 melanoma cells with more moderate ErbB2 expression as targets, comparable cell killing activity of the UniCAR-NK/TM combination and regular CAR-NK cells was found (Fig. 5c, d).